This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Comparison of Nutritional Products for People With Type 2 Diabetes

This study has been completed.
Information provided by:
Abbott Nutrition Identifier:
First received: August 21, 2007
Last updated: July 2, 2008
Last verified: August 2007

Part A: To compare the glucose and insulin responses of a standard tube feeding product to that of a diabetes-specific tube feeding product in individuals with type 2 diabetes.

Part B: To compare the glucose response of a standard tube feeding product to that of a diabetes-specific tube feeding product when consumed by individuals with type 2 diabetes as a sole source of nutrition.

Condition Intervention Phase
Type 2 Diabetes Mellitus Other: enteral nutritional formula Other: Diabetes specific enteral product Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Comparison of Nutritional Products for People With Type 2 Diabetes

Further study details as provided by Abbott Nutrition:

Primary Outcome Measures:
  • Positive area under the curve (AUC) for plasma glucose and mean glucose level [ Time Frame: 240 minutes ]

Secondary Outcome Measures:
  • Adjusted peak values for plasma glucose and serum insulin concentrations and positive AUC for serum insulin concentration [ Time Frame: 240 minutes ]

Enrollment: 33
Study Start Date: August 2007
Study Completion Date: November 2007
Primary Completion Date: October 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: #1
Diabetes specific enteral product
Other: Diabetes specific enteral product
Meal Glucose tolerance test
Active Comparator: #2
Standard enteral feeding
Other: enteral nutritional formula
Meal glucose tolerance test


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Signed and dated informed consent form
  • Type 2 diabetes
  • 18 to 75 years of age
  • Male or non-pregnant, non-lactating female, at least 6 weeks postpartum
  • If female is of childbearing potential, is practicing birth control
  • BMI greater than or equal to 18.5 kg/m2 and less than 40.0 kg/m2
  • Medications, such as antihyperglycemic or thyroid medications or hormone therapy, have been maintained at a constant dosage for at least two months prior to screening visit

Exclusion Criteria:

  • Uses exogenous insulin for glucose control
  • Type 1 diabetes
  • History of diabetic ketoacidosis
  • Current infection; has received corticosteroid treatment in the last 3 months, or has had surgery or received antibiotics in the last 3 weeks
  • Active malignancy
  • Significant cardiovascular event less than 12 weeks prior to study entry
  • End stage organ failure or is status post organ transplant
  • Has an active metabolic, hepatic, or gastrointestinal disease that may interfere with nutrient absorption, distribution, metabolism, or excretion excluding diabetes
  • Chronic, contagious, infectious disease, such as active tuberculosis, Hepatitis B or C, or HIV
  • Taking any herbals, dietary supplements or medications, other than antihyperglycemic medications during the past four weeks that could profoundly affect blood glucose
  • Fainted or experienced other adverse reactions in response to blood collection prior to this study
  • Has clotting or bleeding disorders
  • Allergic or intolerant to any ingredient found in the study products
  • Participant in a concomitant trial that conflicts with this study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00520065

United States, Indiana
Provident Clinical Research and Consulting, Inc.
Bloomington, Indiana, United States, 47403
Sponsors and Collaborators
Abbott Nutrition
Principal Investigator: Kevin C. Maki, PhD Provident Clinical Research and Consulting, Inc.
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Bobbie Swearengin, Director Clinical Research Operations, Abbott Nutrition Identifier: NCT00520065     History of Changes
Other Study ID Numbers: BK06
Study First Received: August 21, 2007
Last Updated: July 2, 2008

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases processed this record on September 21, 2017